ALMS — Alumis Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$10.35
+$0.88 (+9.29%)
Alumis Inc. Common Stock (ALMS) is a biotechnology company listed on NASDAQ. It is led by Martin Babler Ph.D., based in 280 East Grand Avenue, South San Francisco, CA, United States, 94080, with about 182 employees. Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Latest reported ALMS revenue for 2025-09-30 was $2.1M. Net income was -$150.4M. Revenue was down 22.5% from 2025-06-30 to 2025-09-30. ALMS currently screens at market cap $311.6M.
Use this ALMS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALMS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALMS SEC filings page. Lician reads the product cache first so this HTML stays unique to Alumis Inc. Common Stock even when a live quote feed is slow.
About Alumis Inc. Common Stock
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Key Statistics
Market Cap
$311.63M
Volume
587,249
Previous Close
$23.03
Day Range
$23.23 – $24.04
EPS
-$10.38
Revenue
$0.00
Net Income
-$294.23M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
182
ALMS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$294.23M | -$154.99M |
| EPS (Diluted) | -$10.38 | -$72.08 |
Total Assets
$340.99M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$169.53M
Operating Cash Flow
-$255.08M
Free Cash Flow
$0.00
Alumis Inc. Common Stock Company Information
- President, CEO & Chairman
- Martin Babler Ph.D.
- Headquarters
- 280 East Grand Avenue, South San Francisco, CA, United States, 94080
- Website
- www.alumis.com
- Phone
- 650 231 6625
- IPO / Founded
- 2024-06-28
- Sector
- Healthcare
- Industry
- Biotechnology